"On one wall of endocrinologist Kevan Herold's office hangs artwork by a girl who joined one of his type 1 diabetes trials when she was 11 years old. The girl was diagnosed with stage 2 of the disease, a status that meant her own immune system was making at least two types of antibodies that attacked the insulin-producing beta cells in her pancreas."
"But that was before the arrival of teplizumab, a monoclonal antibody approved in late 2022 that delays the advance of the illness and may even halt it at stage 2 in some people. The girl in the trial went on the drug in about 2011. Her disease did move to stage 3but not for almost a decade. She was free of diabetes for eight to nine years."
A girl enrolled in a trial at age 11 after diagnosis with stage 2 type 1 diabetes, characterized by at least two autoantibodies attacking insulin-producing pancreatic beta cells. Stage 2 frequently progresses to stage 3, when insulin therapy becomes necessary. Teplizumab, a monoclonal antibody approved in late 2022, delays progression and can sometimes halt disease at stage 2. A trial participant who began teplizumab around 2011 remained free of clinical diabetes for eight to nine years before progression. Teplizumab's effectiveness varies among individuals and it has encouraged new research and therapeutic development.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]